Loading…

Medical Research Finder

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Multiple Myeloma (MM) / Plasmocytoma

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Multiple myeloma (MM) is a B-cell malignancy for which new treatments are urgently needed

Multiple myeloma (MM) is a cancer of the plasma cells in the Bone marrow (BM) (BM) and is the second most common hematological malignancy worldwide.
Sun et al. 2022a Journal for ImmunoTherapy of Cancer 10: e003975

Multiple myeloma (MM) remains an incurable disease.
Grosicki et al. 2021 Future Oncology 17: 1581–1591

Multiple myeloma is predominantly a disease affecting elderly adults
Möller et …

A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma
Offidani & Corvatta 2018 Future Oncology 14: 319-329
Advances in immunotherapy in multiple myeloma
Boussi & Niesvizky 2017 Curr Opin Oncology 29: 460-466
Antigen-Mediated regulation in monoclonal gammopathies and myeloma
Nair et al. 2018a JCI Insight 3(8): e98259
Denosumab for myeloma bone disease: ready for prime time?
Dimopoulos & Kastritis 2018 Lancet Oncology 19: 277-278
Emerging immune targets for the treatment of multiple myeloma
Sohail et al. 2018 Immunotherapy 14: 265-282
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Drayson et al. 2019
When a Monoclonal Gammopathy Is Not Multiple Myeloma
Derman et al. 2022

5/29/2026